Share on StockTwits

Horizon Pharma (NASDAQ:HZNP) has received a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the stock, Analyst Ratings News reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $20.75.

HZNP has been the subject of a number of recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Horizon Pharma in a research note on Monday, July 7th. They set an “overweight” rating on the stock. Separately, analysts at Zacks upgraded shares of Horizon Pharma from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 2nd. They now have a $17.50 price target on the stock. Finally, analysts at Guggenheim initiated coverage on shares of Horizon Pharma in a research note on Friday, May 30th. They set a “buy” rating and a $31.00 price target on the stock.

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 15.32 on Tuesday. Horizon Pharma has a one year low of $2.11 and a one year high of $18.30. The stock’s 50-day moving average is $15.19 and its 200-day moving average is $12.77. The company’s market cap is $1.125 billion.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Friday, May 9th. The company reported $0.16 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.15. The company had revenue of $51.90 million for the quarter, compared to the consensus estimate of $42.69 million. During the same quarter in the prior year, the company posted ($0.36) earnings per share. The company’s quarterly revenue was up 496.6% on a year-over-year basis. Analysts expect that Horizon Pharma will post $-1.78 EPS for the current fiscal year.

Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.